PEPTIDEPEDIA
加入
监管 · LATAM
R 0112026-08-06

Latin America peptide regulation overview

证据内容以英文维护。

Executive summary

Latin America has no single regional regulatory regime. Each country has its own drug regulatory authority, although PAHO/WHO's PANDRH network promotes harmonisation. Most jurisdictions require marketing authorisation for peptide medicines. Compounding (manipulação / magistral preparation) is permitted within defined legal boundaries but the use of unauthorised peptide bulk substances is generally not allowed.

Common themes

  1. Marketing authorisation: the jurisdictions covered by the linked country pages generally require registration before commercial sale of a peptide medicine, subject to national exceptions. Approved products include , insulins, GnRH analogues, and somatostatin analogues.

  2. Compounding: several reviewed countries allow pharmacy compounding for individual patients, but require: (a) a valid prescription; (b) use of approved or pharmacopoeial raw materials; (c) the product not be a copy of an approved commercial drug.

  3. Research-use-only: in the jurisdictions reviewed, RUO wording was not identified as a safe harbour when surrounding facts show human-use marketing.

  4. Import: commercial import generally requires national authorization. Personal-use, clinical-trial and named-patient pathways vary by country and must be checked in the current national rules.

  5. Enforcement: uneven across the region. Brazil and Mexico have the most active enforcement programmes; the ANMAT (Argentina) and INVIMA (Colombia) have issued alerts against falsified and unapproved peptide products.

National authority directory

AuthorityCountryDedicated atlas page
ANVISABrazilBrazil peptide regulation
COFEPRISMexicoMexico peptide regulation
ANMATArgentinaArgentina, Colombia, and Chile
INVIMAColombiaArgentina, Colombia, and Chile
ISPChileArgentina, Colombia, and Chile

Sport/anti-doping overlay

Prohibited List applies through national anti-doping organisations in each country. Enforcement capacity varies significantly.

Practical interpretation limits

This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.

Related atlas pages: Brazil, Mexico, Argentina, Colombia, and Chile, global framework, and WADA and sport.

Primary sources

  1. PAHO — PANDRH. https://www.paho.org/en/pan-american-network-drug-regulatory-harmonization-pandrh

  2. ANVISA. https://www.gov.br/anvisa

  3. COFEPRIS. https://www.gob.mx/cofepris

  4. ANMAT. https://www.argentina.gob.ar/anmat

  5. INVIMA. https://www.invima.gov.co

  6. ISP Chile. https://www.ispch.cl

问题

Is there one peptide regulator for Latin America?

No. As of 2026-08-06, national authorities make product-authorization and enforcement decisions. Latin America has coordination initiatives but no single regional medicine authorization.

What does PAHO coordination mean?

As of 2026-08-06, PAHO and PANDRH support convergence, capacity, and information exchange. That work does not replace national law or grant a shared product authorization.

Can an enforcement action in one country establish status elsewhere?

No. The actions listed as of 2026-08-06 are dated national records with narrow scopes. They do not establish another country's product status or form a complete regional scorecard.

Where are country-specific Latin American peptide rules documented?

Use the dedicated Brazil, Mexico, and Argentina, Colombia, and Chile pages, then verify the current national authority record. This overview is current to 2026-08-06 and does not replace those country-specific sources.